ArticleDrug delivery letters2011
Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review.
Article in Drug delivery letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 82 citations in OpenAlex.
- Structural basis of human zinc-activated channel (ZAC) signaling and modulation.Cell discovery · 2026Article
- The Impact of Zinc on Cellular Dynamics, Brain Function, and its Therapeutic Potential in Neuronal Regeneration.Molecular neurobiology · 2026Review
- Zinc in psychosis (Review).Molecular medicine reports · 2025Review
- Novel Mutation at Cys225 inMedComm · 2025Article
- Effect of dietary zinc supplementation on the gastrointestinal microbiome and host gene expression in theFrontiers in microbiology · 2025Article
- Neurochemical Research of LOXBlock-1 and ZnSOBiological trace element research · 2024Article
- Article
- A genetically encoded far-red fluorescent indicator for imaging synaptically released ZnScience advances · 2023Article
- Effects of zinc and carnosine on aggregation kinetics of Amyloid-β40 peptide.Biochemistry and biophysics reports · 2022Article
- Identification of the common neurobiological process disturbed in genetic and non-genetic models for autism spectrum disorders.Cellular and molecular life sciences : CMLS · 2022Article
- Restoration of the GTPase activity and cellular interactions of GαScience advances · 2022Article
- Magnesium and Zinc Oxide Nanoparticles fromMolecules (Basel, Switzerland) · 2022Article
- Development of Pharmaceutical Nanomedicines: From the Bench to the Market.Pharmaceutics · 2022Review
- Astrocytes in heavy metal neurotoxicity and neurodegeneration.Brain research · 2021Review
- Concentrations of Essential Trace Metals in the Brain of Animal Species-A Comparative Study.Brain sciences · 2020Article
- Article
- Crosstalk between zinc and free fatty acids in plasma.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2019Review
- Metal Ion Effects on Aβ and Tau Aggregation.International journal of molecular sciences · 2018Review
- Dietary Zinc Supplementation Prevents Autism Related Behaviors and Striatal Synaptic Dysfunction inFrontiers in cellular neuroscience · 2018Article
- Zinc Signal in Brain Diseases.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Homeostasis of metal ions such as Zn(2+) is essential for proper brain function. Moreover, the list of psychiatric and neurodegenerative disorders involving a dysregulation of brain Zn(2+)-levels is long and steadily growing, including Parkinson's and Alzheimer's disease as well as schizophrenia, attention deficit and hyperactivity disorder, depression, amyotrophic lateral sclerosis, Down's syndrome, multiple sclerosis, Wilson's disease and Pick's disease. Furthermore, alterations in Zn(2+)-levels are seen in transient forebrain ischemia, seizures, traumatic brain injury and alcoholism. Thus, the possibility of altering Zn(2+)-levels within the brain is emerging as a new target for the prevention and treatment of psychiatric and neurological diseases. Although the role of Zn(2+) in the brain has been extensively studied over the past decades, methods for controlled regulation and manipulation of Zn(2+) concentrations within the brain are still in their infancy. Since the use of dietary Zn(2+) supplementation and restriction has major limitations, new methods and alternative approaches are currently under investigation, such as the use of intracranial infusion of Zn(2+) chelators or nanoparticle technologies to elevate or decrease intracellular Zn(2+) levels. Therefore, this review briefly summarizes the role of Zn(2+) in psychiatric and neurodegenerative diseases and highlights key findings and impediments of brain Zn(2+)-level manipulation. Furthermore, some methods and compounds, such as metal ion chelation, redistribution and supplementation that are used to control brain Zn(2+)-levels in order to treat brain disorders are evaluated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.